Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Human Genome Sciences Inc HGSI



NDAQ:HGSI - Post by User

Human Genome Sciences Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by mhoganon Jan 17, 2000 2:52pm
212 Views
Post# 1239818

More developments

More developmentsHGSI CEO William Haseltine said in an interview this week, that they don't have any products on the market yet, but have several that are undergoing clinical tests. He went on to say he is confident studies will show patients benefit from what are thought to be the first genomics-derived drugs. A drug that treats breast and ovarian cancer is in Phase I/II trials.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities